Abbott's Humira gets FDA approval for ulcerative colitis

Reading this on a mobile device? Try our optimized mobile version here: http://r.smartbrief.com/resp/dTgbCduTtWCesvojCidmzaCicNFXNJ

October 1, 2012 More than 2,700 companies nationwide are saving on lab supplies, shipping, news distribution, office products and more through the BIO Business Solutions cost-savings program. Find out how. The news summaries appearing in BIO SmartBrief are based on original information from news organizations and are produced by SmartBrief, Inc., an independent e-mail newsletter publisher. The information is not compiled or summarized by BIO. Questions and comments should be directed to SmartBrief at bio@smartbrief.com.   Today's Top Story    Abbott's Humira gets FDA approval for ulcerative colitis The FDA approved Abbott Laboratories' Humira, or adalimumab, to treat moderate to severe ulcerative colitis. The drug is already approved for indications including rheumatoid arthritis and Crohn's disease. Drug Store News (9/28)      Accelerate molecular simulations for your drug discovery research, with Accelrys Discovery Studio ® 3.5! Designed to address the modeling challenge's faced by research scientists, Discovery Studio 3.5 is Accelrys' latest, and most complete modeling and simulation solution for small molecules and macromolecules-based drug design. Register for our webinar and learn about Accelrys Discovery Studio.   Health Care & Policy  Aveo submits kidney cancer drug tivozanib for FDA approval Aveo Oncology filed with the FDA a new-drug application for kidney cancer treatment tivozanib. The filing is based on a study involving 517 patients with advanced renal cell carcinoma who didn't undergo systemic therapy. The drug is co-developed by Astellas Pharma. Boston Herald (9/28)      Intellect and Lonza team up to develop antibody-drug conjugate Lonza and Intellect Neurosciences entered a deal to develop and manufacture Conjumab-A, an antibody-drug conjugate. Lonza will provide preclinical study material for drug optimization and selection for the conjugate, which targets age-related macular degeneration with potential applications for Alzheimer's disease. Pharmaceutical Business Review Online (9/28)      Ariad lung cancer treatment shows promise in Phase I/II trial A Phase I/II study found that Ariad Pharmaceuticals' investigational drug AP26113 reduced tumor size in eight of 11 patients with nonsmall-cell lung cancer who carry a mutation in the ALK gene. Ariad plans to initiate a midstage trial before year-end. Reuters (9/29)      Repligen's muscular atrophy drug enters early-stage development Repligen initiated a trial to assess the safety and pharmacokinetics of RG3039, an experimental drug for spinal muscular atrophy. The Phase Ib study will involve 32 adult healthy volunteers. "Completion of this stage of the RG3039 clinical development program in healthy volunteers, if successful, will provide the necessary foundation for more advanced trials involving SMA patients who are in critical need of a treatment for this devastating disease," Repligen president and CEO Walter Herlihy said. Pharmaceutical Business Review Online (9/28)      Method could reduce tumor potential of iPS cell therapies Mayo Clinic researchers treated induced pluripotent stem cells with a chemotherapy drug to selectively kill the cells that can trigger tumors. The method may make treatments using the cells more effective and safer, according to the study published in the journal Stem Cells Translational Medicine. Medical News Today (9/28)        Company & Financial News  Cytori lands up to $106M to work on stem cell therapy for thermal burns The HHS Biomedical Advanced Research and Development Authority awarded Cytori Therapeutics a contract worth up to $106 million to develop a stem cell treatment for injuries caused by radiation, heat and fire due to a large-scale disaster or attack. The money will go toward all preclinical, clinical, regulatory and technological work needed to obtain approval. The Wall Street Journal/Dow Jones Newswires (9/28), Bloomberg Businessweek/The Associated Press (9/28)      Calif. molecular Dx firm looks to raise $65 million in IPO AutoGenomics, maker of the Infiniti molecular diagnostic tool, hopes to secure $65 million in an initial public offering. The Vista, Calif.-based company will use part of the proceeds to pursue regulatory approvals for its HPV-HR assays and tests related to personalized medicine and women's health. GenomeWeb Daily News (free registration) (9/27)        Food & Agriculture  Bayer CropScience to put $9 billion toward driving growth Bayer CropScience could invest about $6.5 billion on research and development and an additional $2.5 billion in new production capacity and seed processing plants through 2016 as part of its growth strategy, Bayer CEO Sandra Peterson said. "Bayer CropScience aims to lead the way in sustainable crop solutions, and we are heavily investing in R&D, as well as production capacities, to respond to global demand for differentiated crop solutions," Peterson said. Farm Futures (9/25)        Hot Topics  Top five news stories selected by BIO SmartBrief readers in the past week. Regional biotech conference to kick off in Md. (Maryland Gazette) FDA expands approval of Regeneron's eye drug Eylea (Medscape (free registration)) Venture capitalists return to biotechnology, life sciences (Reuters) Onyx-Bayer colorectal cancer drug Stivarga gains FDA approval (CNBC) Report: Biotech revenue, spending on R&D rose in 2011 (PharmaTimes (U.K.)) Results based on number of times each story was clicked by readers.   Industrial & Environmental  An ethanol waiver would undermine support for all biofuels, exec says Renewable Energy Group, the biggest producer of biodiesel in the U.S., called on the Environmental Protection Agency to reject calls for a temporary suspension of the ethanol portion of the Renewable Fuel Standard. An RFS waiver would weaken investor confidence in all biofuels and may even push up retail food costs, said REG President and CEO Daniel Oh. "Food is more available because biofuels have increased overall agricultural production," Oh said. AOL Energy (9/30)      First class, non-stop, global connections. BIO conferences provide strategic access for the biotech community to accelerate business relationships. We catalyze partnerships through our global portfolio of events, including the world's largest biotech gathering, the BIO International Convention. Learn more about BIO events.   News from BIO  Ship with FedEx FedEx is now offering member companies discounts of up to 35% off select FedEx services, both U.S. and international services. The BIO program with FedEx is one of the many cost-savings programs offered by BIO through its Business Solutions program. There is no charge for BIO member companies to participate in any of the BIO Business Solutions programs -- it is a benefit of membership. Learn more about the BIO and FedEx program.      Learn more about BIO -> Conferences  |  Join BIO  |  Media  |  Issues  |  Industry   SmartQuote  Inspiration exists, but it has to find us working." --Pablo Picasso, Spanish artist          This SmartBrief was created for jmabs1@gmail.com   Subscriber Tools       Update account information | Change e-mail address | Unsubscribe | Print friendly format | Web version | Search past news | Archive | Privacy policy Advertise Account Director:  Meryl Harold (202) 407-7828 Download Media Kit   Read more at SmartBrief.com A powerful website for SmartBrief readers including: Industry Home Readers' Choice Search Archive Grab our News Widget Get this RSS Feed Publish your Press Release Download a SmartBrief Mobile app today       Recent BIO SmartBrief Issues: Friday, September 28, 2012 Thursday, September 27, 2012 Wednesday, September 26, 2012 Tuesday, September 25, 2012 Monday, September 24, 2012     Lead Editor:  Tom Parks       Mailing Address: SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004     © 1999-2012 SmartBrief, Inc.® Legal Information